CAP Articulates Plan for Sharing Data from Trials of Preclinical Alzheimer’s Disease
Researchers in Collaboration for Alzheimer’s Prevention frame principles for what kind of data and samples to share and when to share them.
ALL NEWS
612 RESULTS
Sort By:
- Most Recent
- Most Commented
Blood NfL Looks Good as Progression and Outcome Marker
Levels of neurofilament light in blood and spinal fluid of mice reflected brain pathology and changed with treatment.
On Multiple Marker Analysis, Tangles Track Best With Functional Decline
Scientists match up PET scans of neurofibrillary tangles against Aβ imaging, CSF measures, and cognitive tests to see how biomarkers change relative to function.
Plasma Proteomics Study Hints at New Player in Alzheimer’s
A comparison of blood proteins between health and dementia uncovers faulty differentiation signaling, which may have harmful effects on neurogenesis.
Regulators Tell Frontotemporal Dementia Community: We Play on Your Team
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together?
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
CSF Tau Rivals Aβ for Predicting Cognitive Decline
Alois was right: Among cognitively normal middle-aged people followed for more than a decade, memory worsened only in those in whom markers for both amyloid and tau were abnormal.
Meta-Analysis of 21 Years of Alzheimer's Fluid Biomarker Research
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
Does Uber APP Processing Drive Sporadic Alzheimer’s Disease?
In some people, Aβ40 in the cerebrospinal fluid correlates with plaque load in the brain.
Microglial Marker TREM2 Rises in Early Alzheimer’s and on Western Diet
Multiple studies link the amount and processing of this cell surface protein to inflammation and neurodegeneration, although what it does remains unclear.
Midlife Pep Does Not Curtail Alzheimer’s Biomarkers
Exercising the brain and body in middle age may not limit progression of Alzheimer’s pathology.
Can Antibody-Based PET Scans Pinpoint Aβ Oligomers in the Brain?
Researchers report the first successful use of this technology to detect soluble Aβ in the brains of Alzheimer’s mouse models.
Replication a Challenge in Quest for Alzheimer’s Blood Test
Researchers failed to confirm a high-profile, previous 10-lipid panel, but remain bullish on the potential of blood-based metabolites as biomarkers.
TREM2 Goes Up in Spinal Fluid in Early Alzheimer’s
TREM2 levels tracked with tau, but varied widely among patients and carriers of different mutations, leaving it unclear whether TREM2 helps or hurts.
Current Filters
- Biomarkers x